300519 新光药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.4676.0187.55812.76413.660
总资产报酬率 ROA (%)5.0285.4776.81711.51412.536
投入资产回报率 ROIC (%)5.4506.0007.53412.72113.613

边际利润分析
销售毛利率 (%)39.12333.82841.27451.85355.705
营业利润率 (%)26.75921.42527.41636.01941.319
息税前利润/营业总收入 (%)20.68914.32420.07032.95635.951
净利润/营业总收入 (%)22.04918.82623.80030.96035.615

收益指标分析
经营活动净收益/利润总额(%)93.95488.06091.07096.51095.324
价值变动净收益/利润总额(%)5.4658.5425.5673.4364.863
营业外收支净额/利润总额(%)-2.708-0.596-1.330-0.797-0.474

偿债能力分析
流动比率 (X)13.41010.97210.1869.19210.448
速动比率 (X)12.3549.9909.2608.6709.826
资产负债率 (%)7.3278.7119.27410.3229.243
带息债务/全部投入资本 (%)-0.662-0.746-0.790-0.878-0.950
股东权益/带息债务 (%)-15,058.529-13,370.649-12,626.621-11,355.291-10,495.163
股东权益/负债合计 (%)1,264.8591,047.996978.294868.758981.841
利息保障倍数 (X)-3.857-2.054-2.873-11.862-6.950

营运能力分析
应收账款周转天数 (天)16.30714.65422.49620.34519.610
存货周转天数 (天)139.982143.048133.26498.820113.577